In addition to a $147 million increase to the Research Project Grant pool, NCI has added $60 million to targeted research opportunities and a $20 million increase for centers and SPOREs, and $10 million for the National Clinical Trials Network and the NCI Community Oncology Research Program.
When the Senate Committee on Appropriations marked up the fiscal 2019 spending bill, NIH came out ahead—$2 billion ahead.
FDA has approved bevacizumab (Avastin) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection.
FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or who have relapsed after two or more prior lines of therapy.
FDA has approved pembrolizumab (Keytruda) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 as determined by an FDA-approved test.
TESARO Inc. and Genentech entered into a clinical collaboration to evaluate the combination of the PD-L1 antibody atezolizumab (Tecentriq), the MEK inhibitor cobimetinib (Cotellic) and TESARO's PARP inhibitor Zejula (niraparib) in patients with platinum-sensitive ovarian cancer.
FDA has approved, under priority review, Venclexta (venetoclax tablets) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, with or without 17p deletion, who have received at least one prior therapy.
FDA approved Fulphila (pegfilgrastim-jmdb) as a biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.
FDA, EMA accept application for talazoparib in metastatic breast cancer with inherited BRCA mutation
Pfizer Inc. said FDA has accepted for filing and granted Priority Review designation to the company's New Drug Application for talazoparib. The submission is based on results from the EMBRACA trial, which evaluated talazoparib versus chemotherapy in patients with germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.
Women who consumed a low-fat diet had a significantly reduced risk of death after breast cancer. However, women with other cancers who were also on a low-fat diet did not experience the same effect, according to new results from the Women's Health Initiative Dietary Modification trial that were presented at the 2018 American Society of Clinical Oncology Annual Meeting.
